Glycemic control and use of glucose-lowering medications in hospital-admitted type 2 diabetes patients over 80 years

被引:5
|
作者
Gotfredsen, Ditte Resendal [1 ]
Vinther, Siri [1 ]
Petersen, Tonny Studsgaard [1 ,2 ]
Cortes, Rikke [1 ]
Jensen, Thomas Bo [1 ,2 ]
Jimenez-Solem, Espen [1 ,2 ]
Christensen, Mikkel Bring [1 ,2 ,3 ]
机构
[1] Bispebjerg & Frederiksberg Hosp, Dept Clin Pharmacol, Copenhagen, Denmark
[2] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark
[3] Univ Copenhagen, Gentofte Hosp, Ctr Clin Metab Res, Hellerup, Denmark
关键词
OLDER-ADULTS; SEVERE HYPOGLYCEMIA; POTENTIAL OVERTREATMENT; MELLITUS; TRENDS; PEOPLE; ASSOCIATION; PREVALENCE; GUIDELINES; EVENTS;
D O I
10.1038/s41598-020-60818-5
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Treatment guidelines for type 2 diabetes (T2D) recommend avoidance of hypoglycemia and less stringent glycemic control in older patients. We examined the relation of glycemic control to glucose-lowering medications use in a cohort of patients aged>80 years with a diagnosis of T2D and a hospital admission in the Capital Region of Denmark in 2012-2016. We extracted data on medication use, diagnoses, and biochemistry from the hospitals' records. We identified 5,172 T2D patients with high degree of co-morbidity and where 17% had an HbA(1c) in the range recommended for frail, comorbid, older patients with type 2 diabetes (58-75 mmol/mol (7.5-9%)). Half of the patients (n = 2,575) had an HbA1c <48 mmol/mol (<6.5%), and a majority of these (36% of all patients) did not meet the diagnostic criteria for T2D. Of patients treated with one or more glucose-lowering medications (n = 1,758), 20% had HbA(1c)-values <42 mmol/mol (<6%), and 1% had critically low Hba(1c) values <30 mmol/mol (<4.9%), In conclusion, among these hospitalized T2D patients, few had an HbA(1c) within the generally recommended glycemic targets. One third of patients did not meet the diagnostic criteria for T2D, and of the patients who were treated with glucose-lowering medications, one-fifth had HbA(1c)-values suggesting overtreatment.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Second-line Glucose-Lowering Therapy in Type 2 Diabetes Mellitus
    Shin, Jung-Im
    CURRENT DIABETES REPORTS, 2019, 19 (08)
  • [32] Cardiovascular Outcomes Trials of Glucose-Lowering Drugs or Strategies in Type 2 Diabetes
    Gerstein, Hertzel C.
    Shah, Reema
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2018, 47 (01) : 97 - +
  • [33] Dose-Response Effects of Exercise on Glucose-Lowering Medications for Type 2 Diabetes: A Secondary Analysis of a Randomized Clinical Trial
    MacDonald, Christopher S.
    Johansen, Mette Y.
    Nielsen, Sabrina M.
    Christensen, Robin
    Hansen, Katrine B.
    Langberg, Henning
    Vaag, Allan A.
    Karstoft, Kristian
    Lieberman, Daniel E.
    Pedersen, Bente K.
    Ried-Larsen, Mathias
    MAYO CLINIC PROCEEDINGS, 2020, 95 (03) : 488 - 503
  • [34] Health-related quality of life in patients with type 2 diabetes initiating a second-line glucose-lowering therapy: The DISCOVER study
    Nicolucci, Antonio
    Chen, Hungta
    Cid-Ruzafa, Javier
    Cooper, Andrew
    Fenici, Peter
    Gomes, Marilia B.
    Hammar, Niklas
    Khunti, Kamlesh
    Kosiborod, Mikhail
    Leigh, Paul
    Medin, Jennie
    Rathmann, Wolfgang
    Shestakova, Marina, V
    Shimomura, Iichiro
    Siddiqui, Afrah
    Tang, Fengming
    Watada, Hirotaka
    Ji, Linong
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2021, 180
  • [35] Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: an association with glucose-lowering effects
    Takase, Takahiro
    Nakamura, Akinobu
    Miyoshi, Hideaki
    Yamamoto, Chiho
    Atsumi, Tatsuya
    ENDOCRINE JOURNAL, 2017, 64 (03) : 363 - 367
  • [36] Effects of a Mediterranean Eating Plan on the Need for Glucose-Lowering Medications in Participants With Type 2 Diabetes: A Subgroup Analysis of the PREDIMED Trial
    Javier Basterra-Gortari, F.
    Ruiz-Canela, Miguel
    Martinez-Gonzalez, Miguel A.
    Babio, Nancy
    Sorli, Jose V.
    Fito, Montserrat
    Ros, Emilio
    Gomez-Gracia, Enrique
    Fiol, Miquel
    Lapetra, Jose
    Estruch, Ramon
    Serra-Majem, Luis
    Pinto, Xavier
    Gonzalez, Jose I.
    Bullo, Monica
    Castaner, Olga
    Alonso-Gomez, Angel
    Forga, Luis
    Aros, Fernando
    DIABETES CARE, 2019, 42 (08) : 1390 - 1397
  • [37] Multimorbidity, Polypharmacy, Severe Hypoglycemia, and Glycemic Control in Patients Using Glucose-Lowering Drugs for Type 2 Diabetes: A Retrospective Cohort Study Using Health Insurance Claims in Japan
    Ruriko Koto
    Akihiro Nakajima
    Tetsuya Miwa
    Ken Sugimoto
    Diabetes Therapy, 2023, 14 : 1175 - 1192
  • [38] Changes in glucose-lowering drug use before and after cancer diagnosis in patients with diabetes
    Zanders, M. M. J.
    Haak, H. R.
    van Herk-Sukel, M. P. P.
    Herings, R. M. C.
    van de Poll-Franse, L. V.
    Johnson, J. A.
    DIABETES & METABOLISM, 2018, 44 (01) : 22 - 29
  • [39] Changes in HbA1c and frequency of measuring HbA1c and adjusting glucose-lowering medications in the 10 years following diagnosis of type 2 diabetes: a population-based study in the UK
    Lind, Marcus
    Pivodic, Aldina
    Cea-Soriano, Lucia
    Nerman, Olle
    Pehrsson, Nils-Gunnar
    Garcia-Rodriguez, Luis A.
    DIABETOLOGIA, 2014, 57 (08) : 1586 - 1594
  • [40] Intensification of polypharmacy glucose-lowering treatment in type-2 diabetes: When to be cautious?
    Charbonnel, Bernard
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2012, 97 (01) : 3 - 5